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Drug repurposing (repositioning) now is an emerging direction in 
pharmaceutical science and drug development which aims at searching 
new targets for the approved drugs for treatment of completely different 
diseases beyond their initial registration. Among drugs which showed 
their effectiveness in treatment diseases besides their direct targeted 
diseases are such drugs as Rapamycin, immunosuppressive drug, reveals 
itself as promising anticancer drug [1]; metformin being the medication 
for the treatment of type 2 diabetes successfully showed promising as 
anticancer drugs [2]. Today number of drugs successfully repurposed 
steadily grows both in cross disease repurposing and within one class 
of diseases [3].
Current development strategy in drug repurposing changes from 
contingent and sporadic discovery of drug candidates for repurposing 
to a rational strategy that directly focuses on identification of novel 
therapeutics properties and potential targets of the established therapy 
and their combinations. This new strategy is accomplished by the 
development of the novel experimental and computational methods 
and tools which support and accelerate process of drug repurposing 
[3,4]. Adaptation of high throughput technologies such as next-
generation sequencing and microarray techniques to drug repurposing 
aims at the screening of acting drugs and their combinations to discover 
off-target effects and sensitivity profiles of a drug under repurposing 
[5]. Computational bioinformatics methods which facilitate drug 
repurposing are developed based on the biostatistical data analysis of large 
gene expression repositories and interactom databases such as diseases-
genes, disease-drug, drugs-genes, and diseases-drugs-genes databases 
[3,4]. The developments of these up-to-date strategies are supported 
by the government’s initiatives to speed up drug repositioning. For 
example, in the USA, the National Centre for Advancing Translational 
Sciences (NCATS), and National Cancer Institute (NCI) Radiation 
Branch (RRP), has launched the Discovering New Therapeutic Uses 
for Existing Molecules Programme, the Developmental Pathway 
Funding Scheme of the Medical Research Council (MRC) in the UK 
funds the projects on repurposing clinical studies, and the Netherlands 
Organisation for Health Research and Development has funded a project 
on the stimulation of drug rediscovery related to drug repositioning [4].
Beyond obvious financial benefits of drug repurposing, this tendency 
partly stemmed from the recent discoveries in pharmaceutical science 
and shift of a paradigm in drug discovery strategy ‘from one drug for 
one target for one disease’ to systems pharmacology paradigm including 
treatment of systems diseases by combination therapy with increasing 
efficacy [3]. Development of systems biology approaches combined with 
high-throughput omics technologies revealed mechanisms of a complex 
action of drugs due to the complexity and cross talk of cellular signalling 
networks in healthy and pathology. Moreover, it was reported that 22% 
of the gene products (enzymes, receptors, ion channels, kinases) are 
‘druggable’ and half of them already are successful targets by approved 
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drugs that ensures a reach database to explore new potential of the 
approved drugs and their repurpose [3].
Another powerful impulse for drug repurposing was given by new 
knowledge on disease mechanisms and pathology development. In the 
case of cancer therapy, adaptation of non-cancer drugs has become 
possible as a result of acquisition of new knowledge on its connection 
to inflammation, energy metabolism, lipogenesis, immunity, tumour 
environment and other cellular processes promoting malignancy. 
Integrative approach to the investigation of the multiple disease 
mechanisms was successfully developed in the framework of systems 
biology that showed its potential in the development of facilitating 
pathway-focused therapy and discovering of new action modes of 
approved drugs through their repositioning [6]. 
Below we discuss systems biology strategies in drug repurposing 
and highlight three mutually reinforcing approaches which include 
1) cellular pathway analysis aiming at the identification of drug effects 
in downstream and crosstalk pathways relevant to the specific disease; 
2) searching for new targets and new mechanisms of action of the 
repurposed drugs, and 3) bioinformatics approach to comparative 
pathway-based analyse of microarray data on gene expression response 
to treatment by repurposed and approved drugs for identification and 
matching of drug signatures.
We demonstrate these three systems approaches by discussion of 
different aspects of repurposing of the well-established nonhormonal 
drugs for treatment osteoporosis, bisphosphonates (BPs) to cancer 
therapy [7]. BPs such as alendronate, risedronate, zeledronate and 
others used in clinics abrogate osteoclast-mediated bone resorption 
by inhibition of key enzymes in the mevalonate pathway, required 
for synthesis of farnesyl diphosphate (FPP) (Figure 1). FPP is needed 
for lipid post-translation modification of small GTPase including 
Ras, Rho, and Rac that ensures their membrane recruitment leading 
to GTPase co-localisation with their effectors. Inhibition of farnesyl 
pyrophosphate synthase (FPPS) by BPs prevents the prenylation of 
GTPase, accumulation of unprenylated proteins in their inactive form 
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that induce osteoclast apoptosis [7]. High affinity of BPs to mineral 
surfaces of bones brings them close to osteoclasts increasing BP uptake 
that advantages BPs delivery to their target [8].
Increasing evidences of anti-tumour effect of BPs and their 
effectiveness to inhibit cancer cell adhesion, invasion, proliferation and 
induce apoptosis have been reported [8,9]. To the best of our knowledge, 
our laboratory showed for the first time binding of osteoporosis drug 
bisphosphonate to prostate and ovarian cancer tumors non-invasively 
and its potential drug repurposing candidature (Figure 2) [10]. 
Mechanism of anticancer activity of BPs can be established through the 
pathway-based analysis of downstream pathway and cross talk between 
the BP targeted mevalonate pathway and MAP kinase pathway which 
is frequently activated in many cancers and is an effective target of 
numerous anticancer drugs (Figure 1). As discussed above, inhibition 
of FPPS by BPs prevents the prenylation of GTPase RasGTPase that 
blocks its recruitment to membrane in vicinity of receptor tyrosine 
kinase (RTK) and inhibits proliferation signals in MAP kinase pathway 
in cancer cells [8] (Figure 1).
The second approach of the systems biology strategy to drug 
repurposing can be demonstrated by identification of the new targets of 
BPs in RTK signalling pathway relating to cancer progression (Figure 
1). As reported, BPs bind to RTK and inhibit downstream cellular 
signalling in MAP kinase pathways that results in reduction in viability 
of HER-driver lung and breast cancer cells [9,11]. This finding suggests 
a double action of BPs in cancer cells i.e. a new role as RTK inhibitor 
is added to its inhibition action relative to RasGTPase activity due 
to inhibition of its prenylation. Identification of the new BP targets 
unveiled full therapeutic potential of BPs as a new therapeutics to RTK 
driven lung, breast, and colon cancers which can be used alone and in 
combination with chemotherapy and targeted therapy [11].
The third systems approach to drug repurposing mentioned 
above includes bioinformatic analysis of gene expression profiles 
to find common genes networks and pathways which are up- and 
downregulated following the treatment by BPs and established 
anticancer drugs. Results of this analysis can help to identify new 
mechanisms of drug action by comparison of cell responses to 
repurposed drugs with that of drugs with a known mechanism of 
action. The most interest in this analysis is the genes and pathways 
contributing to cancer proliferation which are a typical task of the 
enrichment analysis [12]. In Figure 3 we provided the heatmap for 
a gene expression change following the treatment by three drugs. 
The first one is Herceptin, a HER2 inhibitor being an effective drug 
for HER2 overexpressing breast cancer [13]. The second drug is 
Pertuzumab which blocks receptor heterodimerization of HER2 and 
HER3 [14]. The third drug is alendronate, one of commonly used BPs 
(Figure 3) [7,11,15,16]. 
Figure 1: Scheme of molecule targets of BPs in mevalonate and MAP kinase, 
PI3K/AKT pathways in cancer cells. FPTase-farnesyl protein transferase. 
Figure 2: NIR (near-IR) - tricarbocyanine, cyclic enamine dye conjugated 
alendronate binding to LNCaP ortho tropic prostate cancer model. 
(Papineni unpublished observeations).
Figure 3: The heatmap representing comparison of the significant gene 
expression fold change following Pertuzumab, Herceptin treatments of SKOV3 
ovarian xenograft tumour [15,16] and alendronate treatment of osteoclasts 
from peripheral blood mononuclear cells [11]. 
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Comparison of the gene expression response to these drugs can 
reveal either similarity or difference in gene profiles. Among common 
genes, there are genes being under regulation of MAP kinase and 
PI3K/AKT pathways e.g. EGR1 gene (Early Growth Response 1). 
Further analysis can be used to confirm that alendronate targets the 
same pathway in cancer cells as Pertuzumab and Herceptin. Detailed 
investigation of gene profiles for searching for new targeted pathways 
can be carried out by using computational tools of enrichment analysis 
[12] to identify common pathways affected by the anticancer drugs and 
the repurposed drugs. 
Summarising this brief analysis, we advocate systems biology is a 
powerful approach in supporting and accelerating of drug repurposing 
and can ensure a potential avenue for the discovery of new modes in 
an action for the established drugs and help expand their therapeutic 
potential for the development of a novel therapy.
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